健康志愿者皮下注射超声造影剂Sonazoid用于前哨淋巴结识别:安全性与造影剂剂量分析
本研究在12名健康女性志愿者双侧乳房中上外象限皮下注射Sonazoid(1或2 mL),于注射后0、0.25、0.5、1、2、4、6及24小时行超声造影识别前哨淋巴结。注射后1小时内前哨淋巴结显示为增强结构,两种剂量识别的前哨淋巴结数量无显著差异(P = .74);志愿者仅出现轻微不良事件,均在研究完成前未经干预完全缓解。因此选择较低剂量(1 mL)用于未来临床研究。
要点
- 皮下注射Sonazoid后1小时内可识别前哨淋巴结为增强结构。
- 1 mL与2 mL剂量识别的前哨淋巴结数量无显著差异(P = .74)。
- 仅出现轻微局部不良事件,未经干预完全缓解。
核心结论
- 皮下注射Sonazoid仅引起轻微局部及非显著性不良事件,均未经干预完全缓解;两种剂量间无显著差异,故选择较低剂量1 mL用于未来临床研究。
研究设计与样本
- 研究在12名女性健康志愿者中进行,于双侧乳房中上外象限皮下注射Sonazoid(1或2 mL剂量),分两个不同时间点给药,并于注射后0、0.25、0.5、1、2、4、6及24小时行超声造影检查以识别前哨淋巴结。
关键影像表现/征象
- 注射后1小时内前哨淋巴结可被识别为增强结构。
- 1 mL与2 mL剂量识别的前哨淋巴结数量无显著差异(P = .74)。
- 志愿者仅出现轻微不良事件,均在研究完成前未经干预完全缓解。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Mapping of the lymphatic chain for identification of the sentinel lymph node (SLN) is an important aspect of predicting outcomes for patients with breast cancer, and it is usually performed as an intraoperative procedure using blue dye and/or radiopharmaceutical agents. Recently, the use of contrast-enhanced ultrasound (CEUS) has been proposed as an alternative imaging technique for this mapping. The objective of this study was to evaluate the use of subdermal administration of the ultrasound (US) contrast agent Sonazoid (GE Healthcare, Oslo, Norway) in terms of patient safety and to select the dose to be used for lymphatic applications in humans.
METHODS: This study was performed in 12 female volunteers who received bilateral subdermal injections of Sonazoid (1 or 2 mL dose) in the mid-upper outer quadrant of their breasts at 2 different time points. Contrast-enhanced US examinations were performed 0, 0.25, 0.5, 1, 2, 4, 6, and 24 hours after injection to identify SLNs.
RESULTS: Sentinel lymph nodes were identified within the first hour after injection as enhanced structures, and there was no significant difference by dose in the number of SLNs identified (P = .74). The volunteers only had minor adverse experiences (AEs) that resolved completely without intervention by study completion.
CONCLUSIONS: The subdermal use of Sonazoid in this study showed only minor local and nonsignificant AEs that were completely resolved without any intervention. Two different doses were compared with no significant differences observed between them. Hence, the lower dose studied (1 mL) was selected for use in future clinical studies.
引用
- Machado P, Stanczak M, Liu JB, et al. Subdermal Ultrasound Contrast Agent Injection for Sentinel Lymph Node Identification: An Analysis of Safety and Contrast Agent Dose in Healthy Volunteers. J Ultrasound Med. 2017. PMID: 29205451. doi:10.1002/jum.14502
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。